Navigation Links
Researchers ID Traits of Aggressive Prostate Cancer
Date:6/13/2008

Findings could lead to diagnostic urine test for 10% of men with the disease

FRIDAY, June 13 (HealthDay News) -- The traits of an aggressive type of prostate cancer that occurs in about 10 percent of men with the disease have been identified in hopes of finding a way to diagnose it early, according to researchers.

A team at the Michigan Center for Translational Pathology at the University of Michigan Health System found excess amounts of a gene called SPINK1 (serine peptidase inhibitor, Kazal type 1) in prostate cancers that do not have gene fusions of unrelated cells, a condition that plays a role in at least 50 percent of prostate cancer cases. This led them to believe that SPINK1 is a biomarker -- a molecule in bodily fluids, blood and tissue that can be a signal of a disease -- for a subtype of prostate cancer.

"Because SPINK1 can be found non-invasively in urine, a test could be developed that would complement current urine testing that is used to detect some prostate cancer or future urine tests for gene fusions," Dr. Arul Chinnaiyan, the center's director and senior author of the study, said in a prepared statement.

The findings, published in the June issue of Cancer Cell, also suggest that men with SPINK1-related prostate cancers tend to experience a recurrence of the disease faster than those with other types of prostate cancer.

The discovery came from the researchers analyzing data on 1,800 prostate cancers in search of common pieces of their genetic aberrations.

The National Cancer Institute estimates that this year, 186,320 new cases of prostate cancer will be diagnosed, and more than 28,000 men will die from the disease.

More information

The National Cancer Institute has more about prostate cancer.



-- Kev
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2008)...tient deaths , , SUNDAY, Sept. 7 (Health...injectable diabetes drug Byetta controls blood sug...ion, researchers report. , "Besides obvious imp...the remarkable advantage of both improved efficacy...rability," said Dr. Andre Scheen of the University...
(Date:9/5/2008)...swire/ -- Lieutenant Governor,Catherine Baker Knol...11 as,American Red Cross Blood Donor Day., The Co...oss ask donors,of all blood types to give blood in...11 and to help strengthen community blood supplies... "We all remember those lost on 9/11 in different ...
(Date:9/5/2008)...k, could bring objects out of hiding , ,...someone develops a cloak of invisibility, a team o...the objects it hides. , According to a paper pu...erneath an invisibility cloak would allow invisibl...anghai Jiao Tong University in China said their th...
(Date:9/5/2008)...rthrosurface, Inc.,( http://www.arthrosurface.com ...g systems, announced that it has received approval...ion for its line of focal knee,resurfacing implant...afety,concerns" with the device and granted Phase ...g the safety and efficacy of its,HemiCAP(R) implan...
Breaking Medicine News(10 mins):Health News:Once-Weekly Diabetes Drug Boosts Blood Sugar Control 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2
...0% of youth in the United States cannot boast of a...e case with nearly 15 million// American adults wh...cession. A report from the Agency for Healthcare ...mericans who were not covered under health insuran...
... good trend of decline in the number of suicides. ...realize its goal of scaling down the suicide rates...ealth has enabled some Statistics which portray th... per 100,000 and in 2004 it had dropped to 8.56 de...
...rgos, has confirmed that a new hospital for the Be... Stating that he has directed the Area Health Se...g process for a new hospital. Stating that they wi...future health needs of the Bega community in order...
...’s or KFC restaurants, across the world, have vary...an the levels of the same // food elsewhere. Accor...ew England Journal of Medicine, the researchers an...d's chicken nuggets, KFC hot wings, french fries f...
Other Medicine News:Health News:Construction Of A New Hospital In The Bega Area Confirmed 2
(Date:9/6/2008)...rcent or Greater Concordance Compared to FISH ..., - Company to Include Reporting for HER2 Gene Exp...Reports by End of 2008 -, REDWOOD CITY, Calif., S...nc. (Nasdaq: GHDX ) today announced results from ...ing for HER2 gene expression, as measured by the,c...
(Date:9/5/2008).../PRNewswire-USNewswire/ -- The Florida,Technology,...lorida,Atlantic University researcher Dr. Herbert ... the Center for Molecular Biology and,Biotechnolog...d CHS,Resources LLC (CHS), $184,294 as part of the...tance Grant program (SURECAG). SURECAG was,establi...
(Date:9/5/2008)...., Sept. 5 /- SARcode,Corpo...e LFA-1 inhibitors,to treat inflammatory diseases,...today announced SARcode,s initiation of a Phase 1 ...andidate for T-cell mediated ophthalmic,diseases. ...nt providing,SARcode with an exclusive license to ...
(Date:9/4/2008).... 4 /- Cytopia Limited (ASX:,CYT) tod...ts Phase Ib/II,study of CYT997, the company,s nove...s with an aggressive form of brain cancer known as... trial is the first Phase II efficacy study in hig...any and the second in its,suite of Phase II studie...
Breaking Medicine Technology:Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement 4472 1ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement 4472 2Immunosyn Corporation to Present at FSX 1465 1Immunosyn Corporation to Present at FSX 1465 2New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 1New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 2New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 3New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 4A new key to detecting deadly aortic aneurysms 4466 1A new key to detecting deadly aortic aneurysms 4466 2
...tudy Fails to Meet Primary Endpoint of Improvement... 2007 /PRNewswire-FirstCall/ --,Allos Therapeutics...H, the Company,s pivotal Phase 3 study of Efaproxy...y (WBRT) in women,with brain metastases originatin...its primary endpoint of demonstrating a,statistica...
...SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ --...l company committed to,the discovery, development ...reatment of hepatitis and cancer, announced today ...inical development as an,orally-administered direc... C virus (HCV) infection. , "We have identified a ...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
Aire-Cuf® and Fome-Cuf® tracheostomy tubes with talk attachment are available in I.D. sizes from 5.0 mm to 9.5 mm. , ,Developed to aid the ventilator dependent patient in communicating with
For additional patient safety, the laryngectomy tube is designed with an integral 15 mm ISO termination that can be connected to a ventilator, with or without the inner cannula in place , ,Portex&re
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig
...® Mid-Range Aire-Cuf® Adjustable Neck Flan...he TTS™ tube except this tube features the m...g;., ,Adult Mid-Range Aire-Cuf® Adjustable Ne...ude a trach tie, disconnect wedge, and obturator/i...
Medicine Products: